司美格鲁肽治疗2型糖尿病伴肥胖和肌少症患者的临床观察
x

请在关注微信后,向客服人员索取文件

篇名: 司美格鲁肽治疗2型糖尿病伴肥胖和肌少症患者的临床观察
TITLE: Clinical observation of semaglutide in patients with type 2 diabetes mellitus and concomitant obesity and sarcopenia
摘要: 目的 探讨司美格鲁肽对2型糖尿病(T2DM)伴肥胖和肌少症患者糖脂代谢、身体成分、肌肉功能、炎症和营养相关指标等的影响。方法采用单中心前瞻性随机对照设计,于2023年4月至2025年4月筛选内江市第一人民医院收治的T2DM伴肥胖和肌少症患者166例,采用随机数字表法分为对照组87例、观察组79例。对照组患者给予常规降糖治疗及生活方式管理,观察组患者在对照组基础上加用司美格鲁肽。比较两组患者治疗前与治疗6个月后的糖代谢、胰岛素抵抗、体格、身体成分、肌肉功能、脂代谢、营养、炎症、膳食蛋白质摄入及生活方式执行的相关指标,治疗6个月后的血糖、体重及肌少症相关结局评价指标,以及治疗期间的安全性指标。结果最终有158例患者完成6个月随访,其中对照组83例、观察组75例。两组患者治疗前的各项指标比较,差异均无统计学意义(P>0.05)。治疗6个月后,与治疗前比较,两组患者的空腹血糖(FBG)、餐后2h血糖(2hBG)、糖化血红蛋白(HbA1c)、空腹胰岛素、胰岛素抵抗指数(HOMA-IR)、体重、体重指数(BMI)、甘油三酯、总胆固醇、低密度脂蛋白胆固醇、C反应蛋白、血清铁蛋白水平均显著降低,高密度脂蛋白胆固醇水平显著升高(P<0.05),且观察组较对照组改善幅度更大(P<0.05)。观察组患者的血清白蛋白水平显著高于治疗前及治疗后对照组(P<0.05)。两组患者的骨骼肌指数比较差异无统计学意义(P>0.05),但治疗后观察组患者的握力和步速均显著大于对照组(P<0.05)。观察组患者的HbA1c、FBG及2hBG达标率,HbA1c下降≥1.0个百分点、HOMA-IR下降≥20%、体重下降≥5%、体重下降≥10%、BMI<28kg/m2的比例,握力增加≥2kg、步速增加≥0.05m/s的比例,握力、步速达标率及肌少症状态改善率均显著高于对照组(P<0.05)。两组患者的膳食蛋白质摄入及生活方式执行情况比较,差异均无统计学意义(P>0.05)。两组患者总不良反应发生率比较的差异无统计学意义(P>0.05),均未发生严重不良事件。结论在常规降糖治疗基础上加用司美格鲁肽,可改善T2DM伴肥胖和肌少症患者的糖脂代谢及体重,并有助于改善肌肉功能、炎症状态及营养指标,且短期内未观察到明显的额外骨骼肌量下降。
ABSTRACT: OBJECTIVE To investigate the effects of semaglutide on glucose and lipid metabolism, body composition, muscle function, inflammation- and nutrition-related parameters, and other related indices in patients with type 2 diabetes mellitus (T2DM) and concomitant obesity, and sarcopenia.METHODS This single-center, prospective, randomized controlled study enrolled 166 patients with T2DM and concomitant obesity and sarcopenia at The First People’s Hospital of Neijiang between April 2023 and April 2025. Patients were randomly assigned using a random number table to a control group ( n =87) or an observation group ( n =79). The control group received conventional glucose-lowering therapy and lifestyle management, while the observation group received additional semaglutide. Related indicators of glucose metabolism, insulin resistance, anthropometric parameters, body composition, muscle function, lipid metabolism, nutritional, inflammatory, dietary protein intake, and lifestyle adherence were assessed before treatment and after 6 months of treatment and compared between the two groups. Glycemic-related, weight-related, and sarcopenia-related outcomes at 6 months, as well as safety outcomes during treatment, were also evaluated.RESULTS A total of 158 patients completed the 6-month follow-up, including 83 in the control group and 75 in the observation group. Before treatment, no statistically significant differences were observed in any of the indicators between the two groups ( P >0.05). After 6 months of treatment, compared with before treatment, fasting blood glucose (FBG), 2-hour postprandial blood glucose (2 hBG), glycated hemoglobin (HbA1c), fasting insulin, homeostatic model assessment of insulin resistance (HOMA-IR), body weight, body mass index (BMI), triglycerides, total cholesterol, low-density lipoprotein cholesterol, C-reactive protein, and serum ferritin levels decreased significantly in both groups, whereas high-density lipoprotein cholesterol levels increased significantly ( P <0.05). The magnitude of improvement in these parameters was greater in the observation group than in the control group ( P <0.05). Serum albumin levels in the observation group were significantly higher than that before treatment and that in the control group after treatment ( P <0.05). No statistically significant difference was observed in skeletal muscle index between the two groups ( P >0.05), whereas grip strength and gait speed were significantly greater in the observation group than in the control group after treatment ( P <0.05). The observation group also had higher rates of achieving HbA1c, FBG, and 2 h BG targets; proportions of patients with reductions in HbA1c of ≥1.0 percentage points, HOMA-IR of ≥20%, and body weight of ≥5% and ≥10%, and BMI of <28 kg/m 2 than those in the control group ( P <0.05). The proportions of patients achieving an increase in grip strength of ≥2 kg and in gait speed of ≥0.05 m/s, meeting grip strength and gait speed criteria, and showing improvement in sarcopenia status were also higher in the observation group than those in the control group ( P <0.05). No statistically significant difference was found in dietary protein intake or lifestyle adherence between the two groups ( P >0.05). No statistically significant difference was found in the incidence of total adverse reactions between the two groups ( P >0.05), and no serious adverse events occurred.CONCLUSIONS Adding semaglutide to conventional glucose-lowering therapy may improve glucose and lipid metabolism and body weight in patients with T2DM and concomitant obesity and sarcopenia, while potentially improving muscle function, inflammatory status, and nutritional parameters. No apparent additional loss of skeletal muscle mass was observed in the short term.
期刊: 2026年第37卷第21期
作者: 陈明慧;李先华;范芳;徐艺
AUTHORS: CHEN Minghui,LI Xianhua,FAN Fang,XU Yi
关键字: 司美格鲁肽;2型糖尿病;肥胖;肌少症;糖脂代谢;身体成分;肌肉功能;胰岛素抵抗
KEYWORDS: semaglutide;Type 2 diabetes mellitus;Obesity;sarcopenia;Glucose and lipid metabolism;body composition;muscle function;Insulin resistance
阅读数: 1 次
本月下载数: 0 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!